Loading...
•
Dec 31, 2025
Edwards Lifesciences Q4 2025 Earnings Report
Edwards Lifesciences reported strong fourth quarter and full-year performance in 2025, driven by differentiated strategy and excellent execution.
Key Takeaways
Edwards Lifesciences delivered a strong fourth quarter in 2025, with total sales growing 13.3% to $1.57 billion and adjusted EPS reaching $0.58. The company's TAVR and TMTT segments showed significant growth, contributing to an overall positive financial performance for the year.
Q4 sales increased by 13.3% to $1.57 billion, with constant currency sales growing 11.6%.
Q4 TAVR sales grew 12.0% to $1.16 billion, and Q4 TMTT sales grew over 40% to $156 million.
Adjusted EPS for Q4 was $0.58, reflecting strong profitability.
The company increased its confidence in FY 2026 constant currency sales growth of 8-10% and adjusted EPS of $2.90-$3.05.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Edwards Lifesciences has increased its confidence in achieving its 2026 sales growth rate guidance of 8% to 10% and EPS guidance of $2.90 to $3.05, with Q1 2026 projected sales between $1.55 and $1.63 billion and adjusted EPS of $0.70 to $0.76.
Positive Outlook
- Increased confidence in FY 2026 constant currency sales growth of 8-10%.
- FY 2026 revenue outlook includes TMTT growing 35-45% to $740-$780 million.
- Increased confidence in FY 2026 adjusted EPS of $2.90-$3.05.
- Expects full-year operating profit margin at the high end of the original 28-29% guidance range.
- Projected Q1 2026 total sales between $1.55 and $1.63 billion and adjusted EPS of $0.70 to $0.76.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- No specific negative forward guidance points were explicitly stated in the provided text.
- No specific negative forward guidance points were explicitly stated in the provided text.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...